Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria.
Host immunity is an important but poorly understood determinant of antimalarial efficacy, influencing the outcome of prevention and treatment trials. Variations in host immunity might explain why factors such as host genetics, age, pregnancy, infection with HIV, parasite density, and malaria transmission intensity, can raise or lower apparent cure rates. Recently, attempts have been made to characterise immunological correlates of treatment outcome in Plasmodium falciparum malaria, but not yet for Plasmodium vivax. A better understanding of such correlates might improve trials of antimalarial drugs and provide leads for vaccine development. Greater understanding of the relation between host immunity and treatment outcome is crucial to making informed choices about the use of safe but partly effective drugs for malaria prevention in children and pregnant women. With increasing malaria control efforts worldwide, declining population immunity might alter drug response profiles. Improved methods for assessing antimalarial immunity will strengthen malaria control efforts.
Department of Medicine, University of Melbourne, Melbourne, VIC, Australia. sroger@unimelb.edu.au
Stephen J
SJ
Rogerson
Rushika S
RS
Wijesinghe
Steven R
SR
Meshnick
D000375:Aging; D000962:Antimalarials / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000150:complications / Q000276:immunology* / Q000635:transmission; D044342:Malnutrition; D010963:Plasmodium falciparum; D011247:Pregnancy
D000962:Antimalarials